Diagnosis and treatment of cutaneous disorders in African-American patients

Current Problems in Dermatology

Volumn 10, Issue 3, 1998, Pages 93-126

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; AZELAIC ACID; BARIUM SULFATE; CORTICOSTEROID; GLYCOLIC ACID; HYDROQUINONE; IMMUNOSUPPRESSIVE AGENT; IRRITANT AGENT; METHOXSALEN; PSORALEN; RETINOIC ACID; THIOGLYCOLIC ACID DERIVATIVE;

BOWEN DISEASE; CONTACT DERMATITIS; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; FOLLICULITIS; HUMAN; HYPERPIGMENTATION; KELOID; MELANOMA; MORTALITY; NEGRO; PATIENT SATISFACTION; PHOTOSENSITIVITY DISORDER; PSYCHOLOGICAL ASPECT; PUVA; REVIEW; SARCOIDOSIS; SKIN CANCER; SKIN DISEASE; SKIN INJURY; SKIN PIGMENTATION; SQUAMOUS CELL CARCINOMA; SUN EXPOSURE; VITILIGO;

EID: 0031843221     PISSN: 10400486     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1040-0486(98)90007-2     Document Type: Article

References (174)

1. Caldwell SH, Popenoe R. Perceptions and misperceptions of skin color. Ann Intern Med 1995;122:614-7.
2. Fleischer AB, Feldman SR, Bradham DD. Office based physician services by dermatologists in the US in 1990. J Invest Dermatol 1994; 102:93-7.
3. McLaurin CI. Unusual patterns of common dermatoses in blacks. Cutis 1983;32:352-60.
4. Bolognia JL, Pawelek JM. Biology of hypopigmentation. J Am Acad Dermatol 1988;19:217-55.
5. Szabo G, Gerald AB, Pathak MA, Fitzpatrick TB. Racial differences in the fate of melanosomes in human epidermis. Nature 1969;222:1081-2.
6. Toda K, Pathak MA, Fitzpatrick TB, Quevedo WC, Morikawa F, Nakayama Y. Skin color: its ultrastructure and its determining mechanism. Pigment Cell 1973;1:66-81.
7. Talwar H, Griffiths CEM, Fisher GJ, Russman A, Kruch K, Benrazvis, et al. Differential regulation of tyrosinase activity in skin of white and black individuals in vivo by topical retinoic acid. J Invest Dermatol 1993; 100:800-5.
8. Quevedo WC, Fitzpatrick TB, Szabo G, Jimbow K. Biology of melanocytes. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedburg IM, Austen KF, editors. Dermatology in general medicine. 3rd ed. New York: McGraw-Hill; 1987. p. 224-51.
9. Roselahl I, Szabo G. Ultrastructure of the human melanocyte system in the newborn with special reference to "racial" differences. Pigment Cell 1976:3:1-12.
10. Montagna W, Carlisle KG. The architecture of black and white facial skin. J Am Acad Dermatol 1991;24:929-37.
11. Halder RM, Grimes PE, McLaurin CI, Kress MA, Kenney JA. Incidence of common dermatoses in a predominantly black dermatologie practice. Cutis 1983;32:388-90.
12. Brauner GJ. Cutaneous diseases in black children. Arch Pediatr Adolesc Med 1983;137:488-96.
13. Mosher DB, Fitzpatrick TB, Ortone J-P, Hori Y. Disorders of pigmentation. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedburg IM, Austen KF, editors. Dermatology in general medicine. 3rd ed. New York: McGraw-Hill; 1987. p. 794-876.
14. Kent G, Al'Abadie M. Psychologic effects of vitiligo: a critical incident analysis. J Am Acad Dermatol 1996;35:895-8.
15. Porter JR, Beuf AH, Lemer A, Nordlund J. Psychosocial effect of vitiligo: a comparison of vitiligo patients with "normal" control subjects, with psoriasis patients, and with patients with other pigmentary disorders. J Am Acad Dermatol 1986;15:220-4.
16. Porter JR, Beuf AH. Racial variation in reaction to physical stigma: a study of degree of disturbance by vitiligo among black and white patients. J Health Soc Behav 1991;32:192204.
17. Lemer AB. Vitiligo. J Invest Dermatol 1959;32:285-310.
18. Halder Rm, Grimes PE, Cowan CA, Enterline JA, Chakrabarti SG, Kenney JA. Childhood vitiligo. J Am Acad Dermatol 1987;16:948-54.
19. Kumari J. Vitiligo treated with topical clobetasol proprionate. Arch Dermatol 1984;120:631-5.
20. Kandil E. Treatment of localized vitiligo with intradermal injections of triamcinolone acetonide. Dermatologica 1973;140:195-206.
21. Falabella R, Arrunategui A, Barona M, Alzate A. The minigrafting test for vitiligo: detection of stable lesions for melanocyte transplantation. J Am Acad Dermatol 1995;32: 228-32.
22. Kann SK, Im S, Bong HW, Park Y-K. Treatment of stable vitiligo with autologous epidermal grafting and PUVA. J Am Acad Dermatol 1995;32:943-8.
23. Kenney JA, Grimes PE. How we treat vitiligo. Cutis 1983;43:347-8.
24. Kenney JA. Vitiligo treated by psoralens. Arch Dermatol 1971:103:475-80.
25. Al-Aboosi MM, Afam Z. Oral photochemotherapy in vitiligo: follow-up, patient compliance. Int J Derm 1995; 34:206-8.
26. Pathak MA, Mosher DB, Fitzpatrick TB, Parrish JA. Relative effectiveness of three psoralens and sunlight in repigmentation of 365 vitiligo patients [abstract]. J Invest Dermatol 1980;74:252.
27. Bose SK. Modified Thiersch grafting in stable vitiligo. J Dermatol 1996;23:363-4.
28. Westmore MG. Make-up as an adjunct and aid to the practice of dermatology. Derm Clin 1991;9:81-8.
29. McLaurin CI. Cutaneous reaction patterns in blacks. Derm Clin 1988;6:353-62.
30. James WD, Carter JM, Rodman OG. Pigmentary demarcation lines: a population survey. J Am Acad Dermatol 1987; 16:584-90.
31. Miura O. On the demarcation lines of pigmentation observed among the Japanese, on inner sides of their extremities and on anterior and posterior sides of their medial regions. Tohoku J Exp Med 1951;54:135-40.
32. Leyden JJ, Spott DA, Goldschmidt H. Diffuse and banded melanin pigmentation in nails. Arch Dermatol 1972;105: 548-50.
33. Fox JN, Walton RG, Gottlieb B, Castellano A. Pigmented skin lesions in black newborn infants. Cutis 1979;24:399-402.
34. Cordova A. The mongolian spot. Clin Pediatr 1981;20:714-9.
35. Pratt AG. Birthmarks in infants. Arch Dermatol 1953;67: 302-5.
36. Griffiths CEM, Finkel LJ, Ditre SM, Hamilton TA, Ellis CN, Voorhees JJ. Topical tretinoin (retinoic acid) improves melasma: a vehicle controlled, clinical trial. Br J Dermatol 1993;129:415-21.
37. Kligman AM, Willis I. A new formula for depigmenting human skin. Arch Dermatol 1975;! 11:40-8.
38. Murad H, Shamban AT, Moy LS. Polka-dot syndrome: a more descriptive name for a common problem. Cosmet Derm 1993;March:57-8.
39. Breathnach AS. Melanin hyperpigmentation of skin: melasma, topical treatment with azelaic acid, and other therapies. Cutis 1996;57(Suppl):36-45.
40. Grevelink JM, Duke D, van Leeuwen RL, Gonzalez E, DeCoste SD, Anderson RR. Laser treatment of tattoos in darkly pigmented patients: efficacy and side effects. J Am Acad Dermatol 1996;34:653-6.
41. Bulengo-Ransby SM, Griffiths CEM, Kimbrough-Green CK, Finkel LJ, Hamilton TA, Ellis CN, et al. Topical tretinoin (retinoic acid) for hyperpigmented lesions caused by inflammation of the skin in black patients. N Engl J Med 1993:328:1438-43.
42. Grimes PE, Stockton T. Pigmentary disorders in blacks. Derm Clin 1988:6:271-81.
43. Kimbrough-Green CK, Griffiths CEM, Finkel LJ, Hamilton TA, Bulengo-Ransby SM, Ellis CN, et al. Topical retinoic acid (tretinoin) for melasma in black patients. Arch Dermatol 1993:130:727-33.
44. Pathak MA, Fitzpatrick TB, Parrish JA, Sanchez NP, Sanchez JL. Treatment of melasma with hydroquinone [abstract]. J Invest Dermatol 1981;76:324.
45. Montagna W, Prota A, Kenney JA. Pigmentary disorders that occur in black skin. In: Montagna W, Prota G, Kenney JA, editors. Black skin: structure and function. San Diego: Academic Press; 1993. p. 101-14.
46. Hoshaw RA, Zimmerman KG, Menter A. Ochronosis-like pigmentation from hydroquinone bleaching creams in American blacks. Arch Dermatol 1985:121:105-8.
47. Findlay GH, Morrison JGL, Simson IW. Exogenous ochronosis and pigmented colloid milium from hydroquinone bleaching creams. Br J Dermatol 1975;93:613-622.
48. Taylor CR, Anderson RR. Ineffective treatment of refractory melasma and postinflammatory hyperpigmentation by Q-switched ruby laser. J Dermatol Surg Oncol 1994;20: 592-7.
49. Tse Y, Levine VJ, McClain SA, Ashinoff R. The removal of cutaneous pigmented lesions with the Q-switched ruby laser and the Q-switched neodynium:yttrium-aluminum-garnet laser. J Dermatol Surg Oncol 1994;20:795-800.
50. Kenney JA. Management of dermatoses peculiar to Negroes. Arch Dermatol 1965:91:126-9.
51. Olumide YM, Odunowo BD, Odiase AO. Regional dermatoses in the African race. Int J Dermatol 1990;29:627-35.
52. Brown LA. Pathogenesis and treatment of pseudofolliculitis barbae. Cutis 1983;32:373-5.
53. Dinehart SM, Tanner L, Mallory SB, Herzberg. Acne. keloidalis in .women. Cutis 1989;44:250-2.
54. Debenedette V. Pseudofolliculitis barbae can lead to medical and social problems. Cosmet Dermatol 1993;6:44-6.
55. Kligman AM, Mills OH. Pseudofolliculitis of the beard and topically applied tretinoin. Arch Derm 1973;107:551-2.
56. Hinkel AR, Lind RW. Electrolysis, thermolysis, and the blend. California: Arroway; 1968. p. 150-71.
57. Grimes PE, Arora S, Minus HR, Kenney JA. Dermatosis papulosa nigra. Cutis 1983;32:385-92.
58. Dustan HR. Does keloid pathogenesis hold the key to understanding black/white differences in hypertension severity? Hypertension 1995;26:858-62.
59. Cosman B, Crikelar OF, Ju DM, Gaulin JC, Lattes R. The surgical treatment of keloids. Plast Reconstr Surg 1961;27: 335-58.
60. Ketchum LD, Cohen IK, Masters FW. Hypertrophie scars and keloids: a collective review. Plast Reconstr Surg 1974; 53:140-54.
61. Kelly P. Keloids. Derm Clin 1988;6:413-24.
62. Flint MH. The biological basis of Langer's lines. In: Longacre JJ, editor. The ultrastructure of collagen. Springfield (IL): Charles C Thomas; 1976. p. 132-40.
63. Appleton I, Brown NJ, Willoughby DA. Apoptosis, necrosis, and proliferation: possible implications in the etiology of keloids. Am J Pathol 1996;149:1441-7.
64. Concannon MJ, Barren BB, Adelstein EH, Thornton WH, Puckett CL. The inhibition of fibroblast proliferation by a novel monokine: an in vitro and in vivo study. J Burn Care Rehabil 1993;14:141-7.
65. Tredget EE. The molecular biology of fibroproliferative disorders of the skin: potential cytokine therapeutics. Ann Plast Surg 1994;33:152-4.
66. Bettinger DA, Yager DR, Diegelmann RF, Cohen IK. The effect of TGF-beta on keloid fibroblast proliferation and collagen synthesis. Plast Reconstr Surg 1996;98:827-33.
67. McCauley RL, Chopra V, Li Y-Y, Herndon D, Robson MC. Altered cytokine production in black patients with keloids. J Clinlmmunol 1992;12:300-8.
68. Granstein RD, Rook A, Flotte TJ, Haas A, Gallo RL, Jaffe HS, et al. A controlled trial of intralesional recombinant interferon-gamma in the treatment of keloidal scarring. Arch Dermatol 1990;126:1295-302.
69. Larrabee WF, East CA, Jaffe HS, Stephenson C, Peterson KE. Intralesional interferon gamma treatment for keloids and hypertrophie scars. Arch Otolaryngol Head Neck Surg 1990:116:1159-62.
70. Wong T-W, Chui H-C, Yip K-M. Intralesional interferon alpha-2b has no effect in the treatment of keloids. Br J Dermatol 1994;130:683-5.
71. Al-Khawajah MM. Failure of interferon-alpha 2b in the treatment of mature keloids. Int J Dermatol 1996;35:515-7.
72. Bang RL, Dashti H. Keloid and hypertrophie scars: trace element alteration. Nutrition 1995; 11:527-31.
73. Lawrence WT. In search of the optimal treatment of keloids: report of a series and a review of the literature. Ann Plast Surg 1991;27:164-78.
74. Berman B, Bieley HC. Adjunct therapies to surgical management of keloids. Dermatol Surg 1996;22:126-30.
75. Sclafini AP, Gordon L, Chadha M, Romo T. Prevention of earlobe keloid recurrence with postoperative corticosteroid injections versus radiation therapy. Dermatol Surg 1996;22: 569-74.
76. Conway H, Gillette RW, Findley A. Differential diagnosis of keloids and hypertrophie scars by tissue culture techniques with notes on therapy of keloids by surgical excision and Decadron. Plast Reconstr Surg 1960;25:117-32.
77. Maguire HC. Treatment of keloids with triamcinolone acetonide injected intralesionally. JAMA 1965;192:325-7.
78. Inalsingh CHA. An experience in treating five hundred and one patients with keloids. Hopkins Med J 1974;134:284-90.
79. Escarmant P, Zimmerman S, Amar A, Ratoanina J-L, Moris A, Azalouz H, et al. The treatment of 783 keloid scars by iridium 192 interstitial irradiation after surgical excision. Int J Radiation Oncology Biol Physiol 1993;26:245-51.
80. Klumpar DI, Murray JC, Anscher M. Keloids treated with excision followed by radiation therapy. J Am Acad Dermatol 1994:31:225-31.
81. Nemeth AJ. Keloids and hypertrophie scars. J Dermatol Surg Oncol 1993:19:738-46.
82. Brent B. The role of pressure therapy in management of earlobe keloids: preliminary report of a controlled study. Ann Plast Reconst Surg 1978;1:579-81.
83. Ceilly RI, Babin RW. The combined use of cryosurgery and intralesional injections of suspensions of flourinated adrenocorticosteroids for reducing keloids and hypertrophie scars. J Dermatol Surg Oncol 1979;5:54-6.
84. Rusciani L, Rossi G, Bono R. Use of cryotherapy in the treatment of keloid. J Dermatol Surg Oncol 1993;19:529-34.
85. Wong T-W, Chiu H-C, Chang C-H, Lin L-J, Lui C-C, Chen J-S. Silicone cream occlusive dressing-a novel noninvasive regimen in the treatment of keloid. Dermatology 1996; 192: 329-33.
86. Gold MH. A controlled clinical trial of topical silicone gel sheeting in the treatment of hypertrophie scars and keloids. J Am Acad Dermatol 1994:30:506-7.
87. Janssen de Limpens AMP. The local treatment of hypertrophic scars and keloids with topical retinoic acid. Br J Dermatol 1980;103:319-23.
88. Abeles H, Robins AB, Chaves AD. Sarcoidosis in New York City. Am Rev Respir Dis 1961;84:120-1.
89. Keller AZ. Hospital, age, racial, occupational, geographical, clinical and survivorship characteristics in the epidemiology of sarcoidosis. Am J Epidemiol 1971;94:222-30.
90. Labow TA, Atwood WG, Nelson CT. Sarcoidosis in the American Negro. Arch Dermatol 1964;89:682-8.
91. Takemura T, Shishiba T, Akiyama O, Oritsu M, Matsul Y, Eishi Y. Vascular involvement in cutaneous sarcoidosis. Pathol Int 1997;47:84-9.
92. Kerdel FA, Moschella SL. Sarcoidosis: an updated review. J Am Acad Dermatol 1984;! 1:1-19.
93. Mathur A, Kremer JM. Immunopathology, musculoskeletal features, and treatment of sarcoidosis. Curr Opin Rheumatol 1993;5:90-4.
94. Puryear DW, Fowler AA. Sarcoidosis: a clinical overview. Comprehensive Ther 1996;22:649-53.
95. Sharma OP. Cutaneous sarcoidosis: clinical features and management. Chest 1972;61:320-5.
96. Minus HR, Grimes PE. Cutaneous manifestations of sarcoidosis in blacks. Cutis 1983;32:361-3, 372.
97. MacLaurin CI. Annular facial dermatoses in blacks. Cutis 1983:32:369-70, 384.
98. Burgoyne JS, Wood MG. Psoriasiform sarcoidosis. Arch Dermatol 1972;106:896-8.
99. Isreal HL. The treatment ofsarcoidosis. Postgrad Med J 1970;46:537-40.
100. Selroos O. Treatment of sarcoidosis. Sarcoidosis 1994;! 1: 80-3.
101. Baughman RP, Lower E. The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis. Am Rev Respir Dis 1990;142:1268-71.
102. McLaurin CI. Pédiatrie dermatology in blacks. Dermatol Clin 1988:6:457-73.
103. Fisher AA. The role of age, sex, and color of skin in contact dermatitis. In: Fisher AA, editor. Contact dermatitis. Philadelphia: Lea & Febiger; 1986. p. 69-74.
104. Berardesca E, Maibach HI. Contact dermatitis in blacks. Dermatol Clin 1988;6:363-8.
105. Weigand DA, Haygood C, Gaylor JR. Cell layers and density of Negro and Caucasian stratum corneum. J Invest Dermatol 1974;62:563-8.
106. Berardesca E, Maibach HI. Racial differences in sodium lauryl sulphate induced cutaneous irritation: black and white. Contact Derm 1988;18:65-70.
107. Berardesca E, Maibach HI. Sensitive and ethnic skin: a need for special skin-care agents? Dermatol Clin 1991;9:89-92.
108. Fisher AA. Contact dermatitis in black patients. Cutis 1977; 20:303-19.
109. Anderson KE, Maibach HI. Black and white human skin differences. J Am Acad Dermatol 1979; 1:276-82.
110. Berardesca E, De Rigal J, Leveque JL, Maibach HI. In vivo biophysical characterization of skin physiological differences in races. Dermatologica 1991;182:89-93.
111. Sherertz E, Swartz S. Patch test interpretation on black skin. Am J Contact Derm 1993;4:247-8.
112. Anderson R, Parrish J. The optics of human skin. J Invest Dermatol 1981;77:13-7.
113. Kaidbey KH, Agin PP, Sayre RM, Kligman AM. Photoprotection by melanin-a comparison of black and Caucasian skin. J Am Acad Dermatol 1979:1:249-60.
114. Grange RW. Tanning. Derm Clin 1984;4:189-93.
115. Willis I. Photosensitivity in black patients. Derm Clin 1988; 6:369-75.
116. Herzborg AJ, Dinehart SM. Chronologic aging in black skin. Am J Dermatopathol 1989; 11:319-28.
117. Lim HW, Epstein J. Photosensitivity diseases. J Am Acad Dermatol 1997;36:84-90.
118. Lim HW, Buchness M, Ashinoff R, Soter NA. Chronic actinic dermatitis: study of the spectrum of chronic photosensitivity in 12 patients. Arch Dermatol 1990;126:317-23.
119. Fotiades J, Soter N, Lim HW. Results of evaluation of 203 patients for photosensitivity in a 7.3-year period. J Am Acad Dermatol 1995;33:597-602.
120. Gonzalez E, Gonzalez S. Drug photosensitivity, idiopathic photodermatoses, and sunscreens. J Am Acad Dermatol 1996:35:871-85.
121. Addo HA, Frain-Bell W. Actinie prurigo - a spécifie photodermatosis? Photo Dermatol 1984;l:119-28.
122. Koranda FC. Antimalarials. J Am Acad Dermatol 1981;4: 650-5.
123. Epstein JH. Polymorphous light eruption. Derm Clin 1986;4:243-51.
124. Fusaro RM, Johnson JA. Hereditary polymorphic light eruption of American Indians: occurrence in non-Indians with polymorphic light eruption. J Am Acad Dermatol 1996;34: 612-7.
125. Birt AR, Davis RA. Hereditary polymorphic light eruption of American Indians. Int J Dermatol 1975;14:105-11.
126. Armstrong RB, Solar urticaria. Derm Clin 1986;4:253-9.
127. Ramsey CA, Scrimenti RJ, Cripps DJ. Ultraviolet and visible action spectra in a case of solar urticaria. Arch Dermatol 1970:101:520-3.
128. Kaidbey KH, Messenger L. The clinical spectrum of the persistent light reactor. Arch Dermatol 1984;128:1441-8.
129. Kingston TP, Löwe NJ, Sofen HL, Weingarten DD. Actinic .reticuloid in a black man: successful therapy with azathioprine. J Am Acad Dermatol 1987:16:1079-83.
130. Siegel M, Holley HL, Lee SL. Epidemiologie studies on systemic lupus erythematosus: comparative data for New York City and Jefferson County, Alabama, 1956-65. Arthritis Rheum 1970:13:802-11.
131. Hymes SR, Jordan RE, Arnett FC. Lupus erythematosus. Derm Clin 1986;4:267-76.
132. Smikle MF, Barton EN, Morgan OS, Deceulaer K. Photosensitivity and antinuclear antibodies in black patients with systemic lupus erythematosus. J Assoc Acad Minor Phys 1996;7:53-5.
133. Sutej PG, Gear AJ, Morrison RC, Tikly M, de Beer M, Dos Santos L, et al. Photosensitivity and anti-Ro (SSA) antibodies in black patients with systemic lupus erythematosus (SLE). Br J Rheum 1989;28:321-4.
134. Hazen HH, Freeman CW. Skin Cancer in the American Negro. Arch Dermatol Syph 1950;62:622-3.
135. Fleming ID, Barnwell JR, Burlison PE, Rankin JS. Skin cancer in black patients. Cancer 1975;35:600-5.
136. Scotto J, Fears TR, Fraumeni JF Jr. Incidence of nonmelanoma skin cancer in the United States. Washington (DC): U.S. Government Printing Office; 1981. National Cancer Institute DHHS Report No. NIH 82-2433.
137. Vemeer M, Schmieder GJ, Yoshikawa T, et al. Effects of ultraviolet B light on cutaneous immune responses of humans with deeply pigmented skin. J Invest Dermatol 1991;97:729-34.
138. Mora RG, Bums R. Cancer of the skin in blacks: a review of 128 patients with basal-cell carcinoma. Cancer 1981;47: 1436-8.
139. Halder RM, Bang KM. Skin cancer in blacks in the United ~ States. Dermatol Clin 1988;6:397-405.
140. Mora RG, Perniciaro C. Cancer of the skin in blacks, I: a review of 163 black patients with cutaneous squamous cell carcinoma. J Am Acad Dermatol 1981:5:535-43.
141. Bang KM, Halder RM, White JE, Sampson CC, Wilson J. Skin cancer in black Americans: a review of 126 cases. J NatlMed Assoc 1987;79:51-8.
142. Hubbell CR, Rabin VR, Mora RG. Cancer of the skin in blacks, V: a review of 175 black patients with squamous cell carcinoma of the penis. J Am Acad Dermatol 1988; 18:292-8.
143. White JE, Strudwick WJ, Ricketts WN, Sampson C. Cancer of the skin in Negroes. JAMA 1961;178:845-7.
144. Presser SE, Taylor JR. Squamous cell carcinoma in blacks with discoid lupus erythematosus. J Am Acad Dermatol 1981;4:667-9.
145. Keith WD, Kelly AP, Sumrall AJ, Chhabra A. Squamous cell carcinoma arising in lesions of discoid lupus erythematosus in black persons. Arch Dermatol 1980;! 16:315-7.
146. Martin S, Rosen T, Locker E. Metastatic squamous cell carcinoma of the lip. Arch Dermatol 1979;115:1214.
147. Farah FS, Malta MT, Zeinoun S, Shehadeh SI.. Squamous cell carcinoma and keratoacanthoma in discoid lupus erythematosus. Dermatologica 1974;148:357-61.
148. MacDonald EJ. Epidemiology of skin cancer, 1975. In: Neoplasms of the skin and malignant melanoma: proceedings of the annual clinical conferences on cancer. Chicago: Year Book Medical; 1976. p. 27-41.
149. Weinstock MA. Nonmelanoma skin cancer mortality in the United States, 1969 through 1988. Arch Dermatol 1993;129: 1286-90.
150. Lund HZ. How often does squamous cell carcinoma of the skin metastasize? Arch Dermatol 1965;92:635-7.
151. Mora RG, Perniciaro C. Cancer of the skin in blacks, II: a review of thirty-six patients with squamous cell carcinoma of the lip. J Am Acad Dermatol 1982;6:1005-9.
152. Wurman LH, Adams GL, Meyerhoff WL. Carcinoma of the lip. Am J Surg 1975;130:470-4.
153. Petrovich Z, Kuisk H, Tobochnick N, Kittle RE, Barton R, Jose L. Carcinoma of the lip. Arch Otolaryngol 1979;105: 187.
154. Haas RJ. Curcumcision: a new look at an old controversy. W Va MedJ 1981;77:225-8.
155. Mora RG. Surgical and aesthetic considerations of cancer of the skin in the black American. J Dermatol Surg Oncol 1986; 12:24-31.
156. Freeman RG. Carcinogenesis of skin neoplasms. In: Neoplasms of the skin and malignant melanoma: proceedings of the annual clinical conferences on cancer. Chicago: Year Book Medical; 1976. p. 43-9.
157. Amonette RA, Kaplan RJ. Squamous-cell and basal-cell carcinomas in black patients. J Dermatol Surg 1976;2:158-61.
158. Matsuoka LY, Schauer PK, Sordillo PP. Basal cell carcinoma in black patients. J Am Acad Dermatol 1981;4:670-2.
159. Burns JE, Eisenhauer ED, Jabaley ME, Cruse JM. Cellular immune deficiency in black patients with basal cell carcinoma. J Surg Oncol 1980; 13:129-34.
160. Martin S, Waisman M. Basal cell nevus syndrome in a black patient. Arch Dermatol 1978;! 14:1356-7.
161. Rosen T, Tucker SB, Tschen J. Bowen's disease in blacks. J Am Acad Dermatol 1982;7:364-8.
162. Mora RG, Pemiciaro C, Lee B. Cancer of the skin in blacks, III: a review of nineteen black patients with Bowen's disease. J Am Acad Dermatol 1984;! 1:557-62.
163. Reinigen DS, McCarty KM, Cox E, Siegler HF. Malignant melanoma in black American and white American populations. JAMA 1982:248:1856-9.
164. Crombie IK. Racial differences in melanoma incidence. Br J Cancer 1979;40:185-93.
165. Pack GT, Davis J, Oppenheim A. The relation of race and complexion to the incidence of moles and melanomas. Ann N Y Acad Sci 1963;100:719-42.
166. Goldstein AM, Tucker MA. Etiology, risk factors, and public health issues of melanoma. Curr Opin Oncol 1993;5:358-63.
167. Sober AJ, Lew RA, Koh HK, Barnhill RL. Epidemiology of cutaneous melanoma: an update. Dermatol Clin 1991;9:61729.
168. Stevens NG, Lift JM, Weiss NS. Plantar melanoma: is the incidence of melanoma of the sole of the foot really higher in blacks than whites? Int J Cancer 1990;45:691-3.
169. Weinstock MA. Epidemiology of nonmelanoma skin cancer: clinical issues, definitions, and classifications. J Invest Dermatol 1994;102:45-55.
170. Krememz ET, Smherland CM, Carter RD, Ryan RF. Malignant melanoma in the American black. Ann Surg 1976; 185:533-42.
171. Coleman WP, Loria PR, Reed RJ, Krememz ET. Acral lentiginous melanoma. Arch Dermatol 1980;16:773-6.
172. Amagai N, Williams CM. Malignant melanoma arising from a small congenital nevus in a black child. Arch Dermatol 1993;129:1215-6.
173. Moritz MW, Wallack MK. Survival after malignant melanoma in a black child: a case report and review of the literature. Am J Clin Oncol 1984;7:545-9.
174. Fish J, Smith BE, Cabby JP. Malignant melanoma in childhood. Surgery 1966;59:309-15.